Healthcare & Life Sciences Insights

May 13, 2026

Drug Pricing and Market Access: CMS Update With Rujul Desai

Senior Counselor to CMS, Rujul Desai, joins the Latham team to share updates on a host of current policy topics, from most favored nation pricing and TrumpRx to 340B and program integrity initiatives.

May 12, 2026

DOJ Ramps Up Enforcement on Customs and Tariff Fraud: What Global Companies Need to Know to Mitigate Risk

Latham lawyers discuss what global companies need to know to mitigate risk related to DOJ’s enforcement on customs and tariff fraud. MCLE credit offered.

April 27, 2026

Drug Pricing and Market Access: Highlights From Recent CMS and AHLA Conferences

Missed the CMS Quality Conference or the AHLA Institute on Medicare and Medicaid Payment Issues? Join the Latham team for a discussion of highlights from both events.

January 22, 2026

DOJ Enforcement Priorities: What Medical Device Companies Need to Know

Latham lawyers offer practical insights for medical device companies on mitigating enforcement risk and implementing defense strategies. MCLE credit offered.

January 16, 2026

Latham & Watkins M&A Leaders on the ‘Year of the Mega Deal’

Latham partners Alex Kelly and Paul Kukish, Global Co-Chairs of the firm’s M&A and Private Equity Practice, discuss the surge in global mega deal activity that propelled Latham to the top spot in 2025 M&A and private equity league tables and what’s shaping the deal landscape for 2026.

December 17, 2025

FDA’s QMSR Implementation Is Around the Corner: What Medical Device Companies Need to Know to Be Ready

Latham’s FDA practitioners discuss the new Quality Management System Regulation and what it means for medical device manufacturers, importers, and other stakeholders. MCLE credit offered.

December 16, 2025

Episode 107 — Drug Pricing and Market Access: “Think of It as a Loop” — Succeeding in an Evolving Policy Landscape

Join the Latham team and guest Mike Domanico, a veteran of the pharmaceutical industry, for insights on how organizations can not only survive, but thrive in an ever-shifting policy landscape.

December 15, 2025

Episode 106 — The FDA’s New Playbook: Biosimilars, National Priority Vouchers, and the Plausible Mechanism Pathway

The Latham team unpacks the FDA’s recent actions on the Commissioner’s National Priority Voucher program, the plausible mechanism pathway, and biosimilars — and what they could mean for development timelines, pricing, and market access.

November 24, 2025

Episode 105 — Drug Pricing and Market Access: Government Pricing Assessment Expectations and Benefits

Join the Latham team and guest Eliza Biedziak from Ernst & Young LLP as they discuss what to expect from a government pricing assessment, the role assessments play in compliance, and how assessments can uncover strategic opportunities.

November 03, 2025

Episode 104 — Drug Pricing and Market Access: Deep Dive on the FDA Commissioner’s National Priority Voucher Program Awards

FDA just announced nine awards under the new CNPV program, based in part on drug pricing and onshoring of manufacturing. We review the awards in detail, consider possible agency rationale, and investigate broader implications on pharmaceutical pricing, launch strategies, and market transparency.

October 02, 2025

Episode 103 — Drug Pricing: Takeaways from the Chicago Medicaid Drug Rebate Program Summit

The largest drug pricing conference of the year just concluded in Chicago. Join the Latham team to discuss key themes and highlights, including most favored nation pricing considerations, bona fide service fee changes, and 340B program developments.

July 30, 2025

Healthcare Implications of the One Big Beautiful Bill: What You Need to Know

Members of Latham’s Healthcare & Life Sciences Practice discuss impacts of the OBBB’s healthcare policy provisions. MCLE credit offered.

June 24, 2025

Episode 99 — Drug Pricing: Takeaways From the Philadelphia Pricing and Contracting USA Conference

Join the Latham team and Allan Thoen from Sandoz to hear about the key themes and highlights from one of the year’s significant drug pricing conferences.

June 26, 2025

Access Denied — Navigating the New DOJ Data Security Program With Confidence

Latham’s team of lawyers focusing on data security and national security examine DOJ’s DSP and its potential implications for companies. MCLE credit offered.

June 06, 2025

Episode 98 — Drug Pricing: Takeaways From the MDMA Annual Meeting

One of the country’s largest medical innovation and policy conferences recently concluded in Washington, D.C. Join the Latham team to discuss takeaways from the meeting, including regulatory changes and compliance hot topics.

May 02, 2025

Episode 97 — Drug Pricing: How the Drug Pricing EO Impacts FDA and Overlaps With Grassley-Led Legislation

On April 15, President Trump signed an executive order addressing prescription drug prices. The Latham team analyzes how the EO might impact FDA and dovetails with five bills recently (re-)introduced in the Senate.

March 12, 2025

Episode 95 — Drug Pricing: FDA in the Age of Executive Orders and DOGE

The Department of Government Efficiency, Trump executive orders, and a recent Office of Management and Budget memorandum are making drastic changes at FDA. The Latham team discusses the potential impacts on FDA approval and enforcement activities, including with respect to novel tobacco and nicotine products.

Our Archive

View More